GlassScriptPhysician profile
Syed F Ali
NPI 1093134744
$2,223.46
in general payments reported to CMS, 2019-2025
28 companies · $1,400 in 2025
The $1,400 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.01 · 2023: $94.07 · 2024: $717 · 2025: $1,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,211.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $502.20 | 2024-2025 | |
| Pfizer INC. | $231.20 | 2023-2025 | |
| Biogen, INC. | $206.39 | 2024-2025 | Tysabri, Vumerity, Leqembi |
| Ucb, INC. | $155.85 | 2023-2025 | Zilbrysq, Nayzilam, Rystiggo |
| Neurelis, INC. | $137.11 | 2023-2025 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $76.05 | 2024-2025 | Rexulti |
| Acadia Pharmaceuticals INC | $74.25 | 2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $71.44 | 2024-2025 | Ingrezza |
| Amneal Pharmaceuticals LLC | $70.67 | 2025 | Crexont |
| Genentech USA, INC. | $69.97 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Novartis Pharmaceuticals Corporation | $68.93 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.14 | 2025 | Hyqvia |
| Lundbeck LLC | $53.79 | 2025 | Rexulti, Vyepti |
| Janssen Biotech, INC. | $50.73 | 2025 | |
| Kedrion Biopharma, INC. | $46.18 | 2025 | Rhogam Ultra-Filtered Plus, Kedrab, Albuked |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $43.76 | 2024 | Nourianz |
| Emd Serono, INC. | $42.42 | 2025 | |
| Alexion Pharmaceuticals, INC. | $33.78 | 2024 | Ultomiris |
| Lilly USA, LLC | $33.40 | 2024 | Kisunla |
| Tg Therapeutics, INC. | $31.26 | 2024 | |
| Grifols USA, LLC | $27.87 | 2024 | Gamunex-C |
| Eisai INC. | $23.96 | 2025 | |
| Argenx US, INC. | $23.18 | 2025 | Vyvgart Hytrulo |
| Cycle Pharmaceuticals INC | $19.61 | 2025 | Tascenso Odt |
| Insightec,INC | $17.92 | 2025 | Exablate |
| Teva Pharmaceuticals USA, INC. | $17.34 | 2025 | Austedo Xr |
| Amgen INC. | $16.05 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.